← Retour au Screener

Sector: Santé
Open in Terminal → HYPRLive chart · Key metrics · News · Smart money

Hyperfine

HYPR Micro Cap

Healthcare · Medical Devices

Mis à jour: Jun 18, 2026, 22:21 UTC

1,40 €
+15.11% aujourd'hui
52W: 0,58 € – 1,94 €
52W Low: 0,58 € Position: 60.3% 52W High: 1,94 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
10.36x
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
139 M €
Capitalisation boursière
Croissance du CA
82.6%
Croissance du CA sur un an
Marge bénéficiaire
-226.88%
Marge nette
ROE
-89.78%
Rentabilité des capitaux propres
Beta
Sensibilité au marché
Positions vendeuses
1.98%
% du flottant vendu à découvert
Volume moyen
581,090
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
None
3 analysts
Avg. Price Target
1,89 €
+35.42% upside
Target Range
1,75 € – 2,18 €

About the Company

Sector: Healthcare Industry: Medical Devices Country: United States Employees: 102 Exchange: NGM

Hyperfine en bref

Hyperfine (HYPR) is currently trading at 1,40 € with a market capitalization of 139 M €. The 52-week range spans from 0,58 € to 1,94 €; the current price is 27.9% below the yearly high. Year-over-year revenue growth stands at +82.6%.

💰 Dividende

Hyperfine currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

3 analystes évaluent Hyperfine (HYPR) au consensus : None. L'objectif de cours moyen est de 1,89 €, soit un potentiel de +35.42% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 1,75 € à 2,18 €.

Hyperfine : la thèse d'investissement en détail

Hyperfine (HYPR) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 82.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

À surveiller

  • The analyst consensus price target implies 35.42% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Forte croissance du CA de 82.6% sur un an
  • Marge brute élevée de 51.2% — signe d'un pouvoir de fixation des prix
  • Bilan solide avec faible endettement (D/E 38.19)
Points faibles
  • Actuellement non rentable
  • Free cash flow négatif

Aperçu technique

MM 50 jours
1,27 €
+9.59% vs. cours
MM 200 jours
1,10 €
+26.98% vs. cours
Sous le plus haut 52s
−27.9%
1,94 €
Au-dessus du plus bas 52s
+142.4%
0,58 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

Positions vendeuses
1.98% · Faible
% du flottant vendu à découvert
Dette/Capitaux propres
38.19 · Faible
Dette totale / capitaux propres

Trading Data

50-Day MA: 1,27 €
200-Day MA: 1,10 €
Volume: 4,024,633
Avg. Volume: 581,090
Short Ratio: 1.96
P/B Ratio: 4.58x
Debt/Equity: 38.19x
Free Cash Flow: -14 201 929 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Hyperfine?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut